Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 03, 2024 07:00 ET
|
Werewolf Therapeutics, Inc.
— Company to present an update of its ongoing monotherapy and combination Phase 1/1b trial of WTX-124 in advanced or metastatic solid tumors at ASCO — — Company plans to present interim,...
WELL Launches its Second-Generation AI powered Physician Co-pilot with Chronic Disease Detection Powered by HEALWELL AI
May 02, 2024 08:00 ET
|
HEALWELL AI Inc.
WELL Launches its Second-Generation AI powered Physician Co-pilot with Chronic Disease Detection Powered by HEALWELL AI
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
May 02, 2024 07:30 ET
|
BridgeBio Pharma, Inc.
- Presented cardiac magnetic resonance (CMR) imaging evidence consistent with clinical improvement observed in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in the ATTRibute-CM Phase 3...
BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
May 02, 2024 07:00 ET
|
BridgeBio Pharma, Inc.
The oversubscribed financing was led by Cormorant Asset Management and co-led by Omega Funds with participation from affiliates of Deerfield Management, GV (Google Ventures), EcoR1 Capital, Wellington...
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
May 02, 2024 06:30 ET
|
SpringWorks Therapeutics, Inc.
– Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter – – Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid...
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
May 01, 2024 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...
New YPrime Report Highlights eCOA's Impact on CNS Trials
May 01, 2024 08:00 ET
|
Y-Prime, LLC
YPrime has released a new report, Insights into CNS Clinical Trials, which demonstrates to sponsors how eCOA can help streamline CNS research.
Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update
May 01, 2024 07:00 ET
|
Chimerix, Inc.
– Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data in 2025 and Final OS Data in 2026 – – No Dose Limiting Toxicity in ONC206 Phase 1...
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
April 30, 2024 07:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
Corcept Completes Enrollment in Phase 4 CATALYST Trial
April 29, 2024 08:00 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...